118 related articles for article (PubMed ID: 38010113)
21. [Detection of multiple myeloma cells using multicolor immunofluorescence and flow cytometry].
Tousková M; Maisnar V; Krejsek J; Kopecký O
Vnitr Lek; 1999 Dec; 45(12):708-12. PubMed ID: 10951845
[TBL] [Abstract][Full Text] [Related]
22. [Expression and clinical significance of Notch1 on the membrane of bone marrow CD38(+)CD138(+) plasma cells in the patients with multiple myeloma].
Zhao YR; Fu R; Guan J; Gao S; Liu H; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Wu YH; Song J; Wang HQ; Xing LM; Wang J; Li LJ; Shao ZH
Zhonghua Xue Ye Xue Za Zhi; 2012 Apr; 33(4):274-7. PubMed ID: 22781716
[TBL] [Abstract][Full Text] [Related]
23. [Diagnostic Value of CD27 Antigen in Patients with Multiple Myeloma].
Wang H; Liu L; Liu F; Chen LJ; Qu XY; Li JY; Wu YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1069-1073. PubMed ID: 28823270
[TBL] [Abstract][Full Text] [Related]
24. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma.
Lin P; Owens R; Tricot G; Wilson CS
Am J Clin Pathol; 2004 Apr; 121(4):482-8. PubMed ID: 15080299
[TBL] [Abstract][Full Text] [Related]
25. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
[TBL] [Abstract][Full Text] [Related]
26. Methodological considerations for the high sensitivity detection of multiple myeloma measurable residual disease.
Soh KT; Tario JD; Hahn TE; Hillengass J; McCarthy PL; Wallace PK
Cytometry B Clin Cytom; 2020 Mar; 98(2):161-173. PubMed ID: 31868315
[TBL] [Abstract][Full Text] [Related]
27. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
Pojero F; Flores-Montero J; Sanoja L; Pérez JJ; Puig N; Paiva B; Bottcher S; van Dongen JJ; Orfao A;
Cytometry B Clin Cytom; 2016 Jan; 90(1):91-100. PubMed ID: 26130131
[TBL] [Abstract][Full Text] [Related]
28. Relevance of sample preparation for flow cytometry.
Muccio VE; Saraci E; Gilestro M; Oddolo D; Ruggeri M; Caltagirone S; Bruno B; Boccadoro M; Omedè P
Int J Lab Hematol; 2018 Apr; 40(2):152-158. PubMed ID: 28984084
[TBL] [Abstract][Full Text] [Related]
29. Flow Cytometric Evaluation of Traditional and Novel Surface Markers for the Diagnosis of Plasma Cell Dyscrasias.
Draxler DF; Wutzlhofer LM; Slavka G; Hübl W; Ludwig H; Schreder M; Reynolds J; Willheim M
Indian J Hematol Blood Transfus; 2019 Oct; 35(4):673-682. PubMed ID: 31741619
[TBL] [Abstract][Full Text] [Related]
30. VS38 Identifies Myeloma Cells With Dim CD38 Expression and Plasma Cells Following Daratumumab Therapy, Which Interferes With CD38 Detection for 4 to 6 Months.
Courville EL; Yohe S; Shivers P; Linden MA
Am J Clin Pathol; 2020 Jan; 153(2):221-228. PubMed ID: 31679012
[TBL] [Abstract][Full Text] [Related]
31. Quantification of bone marrow plasma cell infiltration in multiple myeloma: usefulness of bone marrow aspirate clot with CD138 immunohistochemistry.
Matsue K; Matsue Y; Kumata K; Usui Y; Suehara Y; Fukumoto K; Fujisawa M; Narita K; Takeuchi M
Hematol Oncol; 2017 Sep; 35(3):323-328. PubMed ID: 27140172
[TBL] [Abstract][Full Text] [Related]
32. Morphologic and cytogenetic variables affect the flow cytometric recovery of plasma cell myeloma cells in bone marrow aspirates.
Cogbill CH; Spears MD; Vantuinen P; Harrington AM; Olteanu H; Kroft SH
Int J Lab Hematol; 2015 Dec; 37(6):797-808. PubMed ID: 26224420
[TBL] [Abstract][Full Text] [Related]
33. Automated digital enumeration of plasma cells in bone marrow trephine biopsies of multiple myeloma.
Malherbe JAJ; Fuller KA; Mirzai B; Augustson BM; Erber WN
J Clin Pathol; 2022 Jan; 75(1):50-57. PubMed ID: 33234694
[TBL] [Abstract][Full Text] [Related]
34. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
[TBL] [Abstract][Full Text] [Related]
35. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
Ak I; Gulbas Z
Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
[TBL] [Abstract][Full Text] [Related]
36. Multiple myeloma with CD138 changed from positive to negative: A case report.
Yu J; Tan L; Wu Q; Rao Y; Ao J; Yang W; Zou B; Chen J
Cytometry B Clin Cytom; 2021 Mar; 100(2):249-253. PubMed ID: 31967404
[TBL] [Abstract][Full Text] [Related]
37. Tc-99m methoxyisobutylisonitrile bone marrow imaging for predicting the levels of myeloma cells in bone marrow in multiple myeloma: correlation with CD38/CD138 expressing myeloma cells.
Ak I; Aslan V; Vardareli E; Gülbaş Z
Ann Hematol; 2003 Feb; 82(2):88-92. PubMed ID: 12601486
[TBL] [Abstract][Full Text] [Related]
38. [Comparison of minimal residual disease in multiple myeloma patients detected by 8-color panels and next generation flow cytometry].
Wang XF; Wang TT; Zhang ZY; Zhou HX; Zhang YR; Chen WM; Geng CY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jun; 40(6):512-517. PubMed ID: 31340626
[No Abstract] [Full Text] [Related]
39. Syndecan-1 (CD138) immunoreactivity in bone marrow biopsies of multiple myeloma: shed syndecan-1 accumulates in fibrotic regions.
Bayer-Garner IB; Sanderson RD; Dhodapkar MV; Owens RB; Wilson CS
Mod Pathol; 2001 Oct; 14(10):1052-8. PubMed ID: 11598177
[TBL] [Abstract][Full Text] [Related]
40. [Significance of CD138/syndecan-1 for multiple myeloma immunophenotypes].
Zhuang JL; Wang X; Wu YJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1023-7. PubMed ID: 16403272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
